Geleen, July 14th, 2026
We are pleased to share that Basic Pharma, a Geleen-based pharmaceutical company and full-service CDMO, has taken on SHS Capital, a specialist German healthcare investor, as its new majority shareholder. The transaction marks BVP’s 11th successful exit within its health portfolio, and closes out our involvement as a shareholder alongside Particon and co-founder Jacques Havermans.
Founded in 2003 by pharmacist Bob Kool, Basic Pharma has grown from a local contract manufacturer into an integrated pharmaceutical platform, bringing in-house product development, regulatory affairs, pharmacovigilance and GMP manufacturing together under one roof in Geleen, and today serving an international client base across prescription, over-the-counter, and investigational medicinal products. What sets the company apart is its ability to develop, register, and out-license its own product dossiers: under its license & supply model, Basic Pharma licenses internally developed products to distributors and pharmaceutical partners while retaining exclusive manufacturing and market authorisation rights, a structure that has built long-term customer relationships and strong recurring revenues.
The company holds a leading position in the Dutch nasal spray market, and its lean, highly efficient production set-up has allowed it to compete on price internationally as well. Today Basic Pharma employs around 250 people.
With SHS Capital’s backing, Basic Pharma will invest further in production capacity, new products, and international growth. Bob Kool remains CEO and reinvests alongside the new shareholder structure, Harry Relouw continues as CFO, and Cyrille De la Haye, COO, joins the statutory board.
“This transaction marks our 11th successful exit within the BVP Health portfolio. We've watched Basic Pharma grow into a significant player within the Dutch life sciences ecosystem, and we're proud to have contributed to that journey. We're confident that with SHS Capital, the company is well placed to realise the next phase of its growth plans.”
